XNAS · Healthcare · Biotechnology
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.94 | -1.28 | -36.17% | $76,377 | ❌ Miss | +1.37% | +6.47% | — |
| 2026-03-31 | Q4 2025 | -2.11 | -1.47 | +30.33% | $303,385 | ✅ Beat | +5.96% | +1.14% | -9.71% |
| 2025-11-13 |
| Q3 2025 |
| -0.76 |
| -0.66 |
| +13.16% |
| $437,602 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -1.24 | -1.25 | -0.81% | $101,000 | ❌ Miss | -1.48% | -5.93% | +3.70% |
| 2025-03-28 | Q4 2024 | -3.35 | -14.20 | -323.88% | $241,635 | ❌ Miss | +0.00% | -3.80% | +51.63% |
| 2024-11-14 | Q3 2024 | -0.70 | -0.93 | -32.86% | $135,293 | ❌ Miss | -5.58% | -8.00% | +58.95% |
| 2024-08-14 | Q2 2024 | -2.76 | -4.23 | -53.26% | $124,972 | ❌ Miss | +24.06% | +43.61% | +3.79% |
| 2024-05-15 | Q1 2024 | — | 0.36 | — | $80,657 | — | +4.65% | +34.73% | +28.16% |
Showing last 8 quarters.